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PRAbstractAntiphospholipid syndrome (APS) is a systemic autoimmune disease associated with arterial and venous thrombotic events
and recurrent fetal loss. Cardiac manifestations in APS primarily include accelerated atherosclerosis leading to cardiovascular
disease. There is increased cardiovascular mortality in APS. Cardiovascular risk is even higher in secondary APS in lupus
patients. Several traditional and disease-related, autoimmune-inflammatory risk factors are involved in APS-associated
atherosclerosis and its clinical manifestations. Antiphospholipid antibodies (APA), lupus anticoagulant, anti-oxLDL and other
antibodies have been implicated in vascular events underlying APS. The primary and secondary prevention of atherosclerosis
and CAD in these diseases includes drug treatment, such as the use of statins and aspirin, as well as lifestyle modifications.
Apart from atherosclerosis and CVD, other cardiac manifestations may also be present in these patients. Among these
conditions, valvular disease including thickening and vegetations is the most common. APA are involved in the pathogenesis of
Libman–Sacks endocarditis usually associated with SLE. In addition, ventricular dysfunction, intracardiac thrombi and
myxomas, pulmonary hypertension may also exist in APS patients. Early diagnosis of APS, thorough examination of the heart,
control of traditional risk factors by lifestyle modifications and pharmacotherapy, probably anti-inflammatory treatment close
follow-up of APS patients may help to minimize cardiovascular risk in these individuals.
© 2007 Published by Elsevier B.V.
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Antiphospholipid syndrome (APS) is a prothrombotic
state characterized by recurrent venous thrombotic
events including deep venous thrombosis, as well as
pulmonary embolism, arterial thrombosis, recurrent fetal
loss due to placental thrombosis and the presence of
circulating antiphospholipid antibodies (APA) [1].
Thrombophilia present in APS may be associated with
premature and accelerated atherosclerosis [2,3]. Athero-
sclerosis in APS is mediated directly by the proinflam-
matory and procoagulant activity exerted by APA
on vascular endothelial cells (EC), or indirectly via
immuno-inflammatory mechanisms underlying autoan-
tibody-mediated thrombosis [2,4,5]. Cardiovascular
disease (CVD) has been associated with morbidity and
mortality in APS, as well as in other autoimmune dis-
orders including systemic lupus erythematosus (SLE),
rheumatoid arthritis and systemic sclerosis [2,3].
In this review, we describe cardiac manifestations in
APS. We will focus on the two major manifestations:
CVD and valvular disease. Major traditional and non-
traditional risk factors for APS-associated atheroscle-
rosis will be discussed followed by diagnostic and
therapeutic tools used during the management of CVD.
Other cardiac manifestations, such as valvular disease,
Libman–Sacks endocarditis, intracardiac thrombi and
myxomas, diastolic dysfunction and pulmonary hyper-
tension, will also be briefly described (reviewed in
[1,6–12]).
2. Cardiovascular manifestations and accelerated
atherosclerosis in APS
2.1. Epidemiology
In 1993, it was suggested for the first time that APA
may be involved in atherosclerosis [13]. In this study,
possible cross-reactivity between APA and antioxidized






APA and APS have been associated with atheroscle-
rosis, as well as CVD, cerebrovascular and peripheral
arterial diseases [3,14–20]. Premature atherosclerosis
may first occur in the lower limbs [21]. In a preliminary
report of three patients, severe systemic atherosclerosis
including aortic occlusion was associated with high
serum levels of anticardiolipin (aCL) autoantibodies and
homocysteine [22]. A prospective study of 116 con-
secutive patients with recent onset intermittent claudi-
cation revealed, that some kind of thrombophilia
occurred in about 25% of patients. In addition, more
than half of the patients had elevated serum APA con-
centrations [21]. APA has been associated with mortality
in CAD [18]. These results suggested that APA may be
involved in the evolution of progressive atherosclerosis.
2.2. Traditional and autoimmune-inflammatory risk
factors for atherosclerosis in APS
A number of traditional cardiovascular risk factors,
such as hyperlipidemia, diabetes mellitus, smoking,
obesity, arterial hypertension and sedentary lifestyle
were assessed in APS patients (Table 1). None of these
Framingham risk factors showed any difference be-
tween APS patients and the general population [5].
Therefore, APS-associated atherosclerosis may rather be
explained by inflammatory and immunopathological
factors, primarily APA.
APA including aCL and anti-β2GPI antibodies, as
well as lupus anticoagulant (LA) exert direct pro-
inflammatory and procoagulant activity on the endo-
thelial surface. APA also trigger an inflammatory cas-
cade [2,23]. Others and we showed correlation between
serum levels of aCL and anti-β2GPI antibodies and the
incidence and severity of acute coronary syndrome,
myocardial infarction and stroke [14–16]. APA-induced
arterial events are the most pronounced in SLE-asso-
ciated secondary APS, where traditional and non-
traditional risk factors are multiplied and atherosclerosis






















































































Traditional and non-traditional risk factors for atherosclerosis and
cardiovascular disease in antiphospholipid syndromet1:2













t1:15 Increased vessel wall
angiogenesis
t1:16 Defective apoptosis





In a recent retrospective analysis of 1519 APA-
positive patients, among them 637 with clinical APS, we
detected venous thrombotic events more frequently in
patients having circulating lupus anticoagulant (LA) in
comparison to patients with other types of APA. In
contrast, coronary, carotid and peripheral arterial throm-
bosis occurred more often in patients with elevated
serum levels of IgG or IgM APA, including aCL or anti-
β2 glycoprotein I (β2GPI) antibodies. Our results sug-
gest that mainly APA are involved in arterial thrombotic
events underlying APS [26].
We and others have suggested the involvement of
APA in acute coronary syndrome (ACS) [16,20,27]. We
found an increased frequency of anti-β2GPI antibodies
in ACS compared to controls. Anti-β2GPI antibodies of
the IgA isotype seemed to be the most relevant for the
onset and outcome of ACS. Anti-β2GPI antibodies
were also associated with previous stroke in ACS
patients [16]. There is evidence that increases in serum
APA levels precede the clinical manifestation of ACS
[16,20]. Coronary restenosis occurred more frequently
in APA positive ACS patients [27].
There is a cross-reactivity between aCL and other
antibodies, such as anti-oxLDL, anti-HDL or anti-apoli-
poprotein A-I IgG [2,3,14,23,28]. Both APA and anti-
oxLDL are atherogenic and they can bind to neoepitopes
of oxLDL, as well as to oxLDL–β2GPI complexes
[2,28]. Autoantibodies against these complexes have
been detected in APS, as well as SLE patients [2,29].
Serum levels of autoantibodies to the oxLDL ligand-
β2GPI complexes were significantly higher in APS
patients in comparison to SLE patients without APS or
healthy subjects [2,29]. Both APA and anti-oxLDL may






Heat-shock proteins (hsp), oxLDL and β2GPI are
present within atherosclerotic lesions [14,30]. Others
and we detected the β2GPI cofactor in the wall of large
arteries in the vicinity of CD4+ T cell infiltrates. Macro-
phages and endothelial cells bind to β2GPI during the
atherosclerotic process [14–16,30]. Furthermore, im-
munization with these autoantigens triggers an immune
response leading to the progression of atherosclerosis
[2,14,28,31]. A humoral response to β2GPI and hsp in
the atherosclerotic plaque may play a role in the
pathogenesis of stroke. The production of IgA anti-
β2GPI and IgG anti-hsp60/65 antibodies is indepen-
dently associated with increased risk for stroke [32].
Autoantibodies against malondialdehyde-modified
lipoprotein(a) [Lp(a)] were detected in 104 APS
patients. This supports the potential role of oxidative
processes in atherogenesis [2,33]. APA also induce
nitric oxide and superoxide production. Furthermore,
direct interference of APA with the antioxidant enzyme
paraoxonase also contributes to accelerated atheroscle-
rosis [2,34].
All the above described data support the pathogenic
role of APA and other autoantibodies in the develop-
ment of APS-associated atherogenesis. In contrast,
the passive administration of monoclonal antibodies
against some phospholipids and LDL antigens pro-
tected against atherosclerosis in LDL receptor-deficient
mice [2,3,34,35]. This controversy may arise from the
fact that different types of autoantibodies, such as
“pathogenic” and “protective” may exist, and in some
studies these two types of antibodies are assessed
together [34]. Therefore, antibodies with different
pathogenic roles should be dissected.
2.3. Overlapping patterns in the pathogenesis of APS
and atherosclerosis
Endothelial injury caused by several factors includ-
ing shear stress, viruses, homocysteine, autoantibodies,
immune complexes, complement activation, oxidative
stress is a key event in atherogenesis [36–39]. As de-
scribed above, APA can bind to neoepitopes of oxLDL,
as well as to oxLDL-β2GPI complexes [28,36]. This
promotes enhanced uptake of oxLDL by macrophages
via scavenger receptors and the transition of macro-
phages to foam cells [36].
Endothelial injury then results in endothelial
dysfunction and a perpetuating inflammatory response,
which leads to the progression of atherosclerosis. This
inflammatory response includes increased production
of pro-inflammatory cytokines, chemokines and other










































































































adhesionmolecules on leukocytes and endothelial cells.
The enhanced production of these mediators then
stimulate further leukocyte adhesion and recruitment
to the vessel wall, as well as the proliferation of mono-
cyte/macrophages, vascular endothelial and smooth
muscle cells. Macrophages turn into foam cells leading
to the formation of fatty streaks and atheromatous
plaques. The production of matrix-degrading proteases
and tissue factor by macrophages eventually lead to
plaque rupture and thrombus formation [2,3,12,36,40].
2.4. Diagnostic aspects of APS-associated CVD:
Imaging and laboratory
Imaging techniques allow the detection of subclinical
atherosclerosis by revealing early endothelial dysfunc-
tion, abnormalities of circulation or atherosclerotic
plaques [2,19]. Common carotid B-mode ultrasound is
suitable for the detection of atherosclerotic plaques and
for the assessment of common carotid intimal-medial
thickness (ccIMT) [2,41]. ccIMT is regarded as an early,
sensitive marker for atherosclerosis, whereas endothelial
dysfunction precedes manifest atherosclerosis [2,19].
Coronary artery calcification can be assessed by using
electron beam computed tomography [42]. Early endo-
thelial dysfunction in APS can be assessed by flow-
mediated (FMD) and nitroglycerine-mediated (NMD)
vasodilatation of the brachial artery using high-resolu-
tion ultrasound [2,19,43].
Unfortunately, only very few such studies have been
performed with respect to APS. Early endothelial dys-
function and increased common carotid intimal-medial
thickness (ccIMT) have been observed in APS [2]. We
reported abnormal FMD and increased ccIMT in 46
patients with primary APS. The FMD in patients (3.4%)
was significantly lower than that in sex- and age-
matched controls (8%). ccIMT was significantly higher
in APS (0.71 mm) in comparison to controls (0.58 mm).
This was associated with increased production of von
Willebrand antigen in APS [19]. Others found a cor-
relation between aCL IgG antibody levels and ccIMT.
These data support the atherogenic role for APA
[2,3,44]. Premenopausal women with APS had an
increased prevalence of carotid and femoral plaques
using ultrasound. This was not associated with APA or
any other predictors of atherosclerosis tested including
age, lipid levels or cumulative corticosteroid use [2].
Again, there is difference between primary and sec-
ondary APS in this context, as higher number and earlier
development of carotid plaques were observed in SLE-
associated APS in comparison to primary APS. Second-






ditional risk factors for CVD [2,25,45]. Therefore the role
of APA and/or APS as independent risk factors for ath-
erosclerosis and CVD is difficult to assess as the majority
of studies include patients with APS secondary to SLE
[2]. Among the few primary APS studies, the prevalence
of ccIMTwas investigated in 28 patients and 28 age- and
sex-matched controls. Significantly increased ccIMT and
decreased lumen diameter were found in primary APS
compared to controls. APS patients with higher ccIMT
exerted a 3-fold higher risk for stroke than those without
increased ccIMT [46]. In another study, ccIMTwas higher
among 20 primary APS patients in comparison to 20
matched controls. Especially patients N40 years old had
evidence for atherosclerosis [2].
Regarding laboratory markers, it is evident that the
determination of APA and LA is necessary to diagnose
APS. Furthermore, the assessment of anti-dsDNA and
other autoantibodies may confirm an underlying lupus
in secondary APS [1]. High sensitive CRP (hs-CRP) is a
marker of inflammation and, as described above, the
determination of hs-CRP independently predicts CVD,
stroke and peripheral artery disease. In a recent cohort of
55 APA positive patients with recent stroke, elevated
levels of hs-CRP were associated with an increased rate
of recurrent or residual symptoms [47].
2.5. Management of atherosclerosis and CVD in APS
There has been a consensus report on themanagement
of cardiac disease in APS [48]. Atherosclerosis treatment
strategies in primary and secondary APS include an
aggressive control of all traditional risk factors including
hyperlipidemia, hypertension, smoking, obesity, diabe-
tes mellitus should be performed by using both drug
treatment and changes in lifestyle [2,48]. There is
no solid evidence from randomized, controlled trials
indicating the preventative action of any drugs in APS
[2,23]. Medications used to prevent atherosclerosis and
to treat CVD in APS include antiplatelet agents and
anticoagulants, as well as statins, folic acid, B vitamins
and, as described later, possibly antimalarial agents
[2,48].
Statin therapy significantly reduces the risk of CVD
[23,49]. Apart from their beneficial effects on lipid
profile, statins reduce serum CRP levels, directly in-
hibit interferon-γ-induced MHC class II expression
and thus suppress T cell-driven autoimmunity [23].
Statins also prevent endothelial dysfunction [49].
Statin therapy should be considered in APS patients,
if LDL-C N3.4 mmol/l, or when LDL-C is persistently
N2.6 mmol/l even after weight reduction and dietary











































































































Aspirin has been used for a long time to prevent CVD
and reduce mortality in the general population [23].
Regarding APS, in a decision analysis model, aspirin
intake in 40-year-old lupus patients was estimated to
gain 3 months of quality-adjusted survival in APA
negative, and 11 months in APA positive individuals
[51]. APA positive SLE patients should be prescribed
aspirin if there are no contraindications [48,50]. As
aspirin treatment has not been shown to add any benefit
over warfarin alone, the use of aspirin may not be
necessary in warfarin-treated patients [52]. Folic acid
and B vitamins may be used liberally [48]. Unfortu-
nately, these data only suggest the potential benefit of
the use of such agents in APS, but there is no high-
quality clinical evidence in this context.
Anti-inflammatory treatment utilized in APS may be
pro- or antiatherogenic [23,36,53]. Corticosteroids are
atherogenic by unfavorably affecting body fat distribu-
tion, blood pressure and glucose metabolism leading to
dyslipidemia, hypertension and diabetes mellitus
[23,36]. However, other studies were unable to confirm
an association between glucocorticoid use and athero-
sclerosis [23,36]. Controversy arises from the dual
action of glucocorticoids, as they are atherogenic, but,
on the other hand, also anti-inflammatory [23]. Thus, the
patients' own anti-inflammatory and metabolic response
to glucocorticoid therapy may influence the individual
therapeutic strategy to be used in a single APS patient
[2,3,23,36] (Table 1).
In contrast to corticosteroids, antimalarial drugs,
such as chloroquine and HCQ, may exert evident
antiatherogenic properties [23]. In vitro studies suggest
that antimalarials may inhibit platelet aggregation and
the thrombogenic effects of APA [54,55]. Despite these
potential benefits, the antiatherogenic effects of antima-
larial drugs need to be clinically confirmed.
3. Other cardiac manifestations in APS
3.1. Valvular disease
Apart from atherosclerosis-induced CVD, valvular
involvement including thickening and vegetations is
the most common cardiac manifestation in APS [1,6–
12,56]. Valvular disease including thickening of the
mitral valve cusps and valvular vegetations are more
frequently seen in patients with primary APS than in
non-APS SLE patients [57]. In SLE, 48% of APA
positive patients but only 21% of APA negative
patients had valvular involvement [6,8]. In some stud-
ies, valvular disease has been associated with higher






tionship [58,59]. Valvular thickening is the most
common abnormality detected by echocardiography.
The mitral valve is most commonly involved followed
by the aortic valve. Hemodynamic changes may occur:
mitral and aortic regurgitation have been observed in
22% and 6% of APS patients, respectively [6,8].
However, most cases are asymptomatic and can only
detected by thorough chest auscultation, echocardiog-
raphy or at autopsy. Altogether 4–6% of SLE and
primary APS patients develop severe valvular regur-
gitation requiring valve replacement in about half of
these patents [6–9].
Early reports of the link between APA and SLE-
associated valvular vegetations date back to the mid
1980s [6,9]. This so-called “Libman–Sacks endocardi-
tis” has been classically described in lupus patients as
verrucous endocarditis of valve leaflets, papillary
muscles and the mural endocardium [61]. Today the
mitral valve is involved most often, followed by the
aortic and tricuspid valves. Valvular disease is usually
not clinically significant [6,8,62]. Some studies suggest
that APA may play an important role in the development
of vegetations in Libman–Sacks endocarditis [6,8,9,63].
Studies with two β2GPI-related peptides also mimick-
ing common pathogens suggested that Libman–Sacks
endocarditis may have infectious origin [63]. In ad-
dition, valvular disease is detected in about one-third of
APS patients and valvular thrombus formation may
exist in APS [58,59].
Regarding the pathogenesis of APA-associated val-
vular disease, when histological analysis of valve
specimens was performed, non-inflammatory lesions
were characterized by intravalvular capillary thrombo-
sis, laminar or verrucous superficial thrombosis, vascu-
lar proliferation, fibrosis and calcification [6–9].
Positive staining for aCL, human immunoglobulins
and for complement was observed in the subendothelial
layer of the leaflets and cups [6,64]. Circulating APA
may bind to the valvular endothelium leading to endo-
cardial damage, resulting in superficial thrombosis and
subendocardial inflammatory infiltration. These events
eventually lead to fibrosis and calcification [6,8].
Valvular disease, especially Libman–Sacks endocardi-
tis, may resemble rheumatic fever. Both APS and
rheumatic fever include cardiac and central nervous
system involvement. There may be a molecular mimicry
between pathogens and autoantigens. APS may be
associated with streptococcal infection. In addition, a
cross-reactivity between antibodies to streptococcal M-
protein and APA has been observed [6,65].
A consensus committee recommend anticoagulation





















































































































should be prophylactically treated with aspirin. The
administration of corticosteroids in valvular disease is
not recommended, however, if there is clinical evidence
for inflammatory valvulitis, anti-inflammatory treatment
may be introduced [48].
3.2. Other cardiac manifestations
In one study, 10 patients with primary APS and 10
controls underwent echocardiography I order to assess
systolic and diastolic function. APS patients had de-
creases in the peak early filling velocity, in the ratio of
peak early to peak atrial filling velocities and in the
mean deceleration rate of early filling in comparison to
healthy matched controls. The left ventricular systolic
function appeared to be normal [66].
There have been scattered reports of intracardiac
thrombi and myxomas, as well as pulmonary hyperten-
sion in APS [10,12,56]. Intensive anticoagulation
should be introduced in intracardiac thrombi and pul-
monary hypertension [48]. The management of pulmo-
nary hypertension also includes prostaglandins or
endothelin antagonists [48]. A case of interauricular
communication detected by transesophageal echocardi-
ography has been reported [56]. These rare manifesta-
tions could only be diagnosed if thorough examination
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